Good first six months in 2009 for Boehringer Ingelheim
Boehringer Ingelheim again posted gratifying growth in local currency (+8.3 percent) over the previous year in the first six months of 2009. Consolidated in euro, this reflected growth of + 15.7 percent thanks to the positive exchange rates, with net sales of EUR 6,388 million compared with EUR 5,522 million in the first six months of the previous year.
The operating income developed equally well over the previous year. Currency effects played their part here, too, adding to the positive development of the individual businesses.
In the first six months, net sales of Boehringer Ingelheim again outpaced the growth on the world pharma market.
Prof. Dr Dr Andreas Barner, Chairman of the Board of Managing Directors: "We have posted growth in our business areas Human Pharmaceuticals, thanks in particular to the success of our innovative prescription medicines, and in Animal Health, thanks to the growth in the segment of vaccines. Despite the negative impact in some areas as a result of the financial crisis, local business development in the first half of 2009 shows that Boehringer Ingelheim is maintaining its growth course, virtually unchanged, and continues to outpace the pharmaceutical market," said Andreas Barner.
Other news from the department business & finance
